Overall, ER+ breast cancer ARPs indicated reduced metabolic activity across many cell types and particularly the endothelium, enrichment of tumor-supportive inflammatory activity in myeloid cells and attenuated IFN responses in cancer cells with age. This evidence concerns the gene ESR1 and breast carcinoma.